US 10005811
β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted A61KA61K31/7076A61P
Quick answer
US patent 10005811 (β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment) held by Atea Pharmaceuticals, Inc. expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Atea Pharmaceuticals, Inc.
- Grant date
- Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/7076, A61P, A61P31/14